We claim:

1. An antibody formulation suitable for pharmaceutical infusion or subcutaneous injection, comprising:

an anti-APRIL antibody at a concentration of between about 20 mg/mL to about 190 mg/mL;

about 10 mM L-histidine;

about 75 mM L-arginine;

about 3% wt % sorbitol;

about 0.01 wt % polysorbate 20; and

a pH of about 6.0 to about 6.6;

wherein the formulation (i) has a viscosity of about 16 cP or less, (ii) does not comprise glutamic acid or its salt, (iii) has an osmolality of between about 250 mOsm/kg to about 390 mOsm/kg, and (iv) has an OD330 of less than about 1.0.

2. An antibody formulation according to claim 1, wherein the formulation maintains at least 96% purity of the anti-APRIL antibody following storage at 2-8ºC for 9 months following manufacture of the formulation.

3. An antibody formulation according to claim 2, wherein the formulation maintains at least 95% purity of the anti-APRIL antibody following storage at 25ºC for 6 months following manufacture of the formulation.

4. An antibody formulation according to one of claims 1-3, wherein the formulation has a second virial coefficient of $2.5x10^{-5}$ mol·mL/g^2 or greater measured at 25ºC.

5. An antibody formulation according to one of claims 1-4, wherein the formulation has a calculated isoelectric point of about 7.4 or greater.

6. An antibody formulation according to one of claims 1-5, wherein the anti-APRIL antibody in the formulation is at a concentration of about 150 mg/mL.

7. An antibody formulation according to claim 6, wherein the formulation has an osmolality of between about 290 mOsm/kg to about 390 mOsm/kg.

8. An antibody formulation according to one of claims 6 or 7, wherein the formulation has an OD330 of about 0.8 or less.

9. An antibody formulation according to one of claims 1-5, wherein the anti-APRIL antibody is at a concentration of about 20 mg/mL.

10. An antibody formulation according to claim 9, wherein the formulation has an osmolality of between about 293 mOsm/kg to about 333 mOsm/kg.

11. An antibody formulation according to one of claims 1-10, wherein the anti-APRIL antibody is a humanized antibody comprising a heavy chain variable region.light chain variable region pair selected from the group consisting of VH11.VL15, VH12.VL15, VH13.VL15, VH14.VL15, VH14_1.VL15, VH14_1C.VL15, VH14_1D.VL15, VH14_1E.VL15, and VH14_1G.VL15.

12. An antibody formulation according to one of claims 1-11, wherein the formulation is free of glycine, carbonate, HEPES, phosphate, citrate, and acetate.

13. A single-use or multi-use vial comprising the antibody formulation of one of claims 1-12.

14. The single-use or multi-use vial of claim 13 containing a volume of between 0.5 mL and 50 mL of the formulation having an anti-APRIL antibody concentration of between about 20 mg/mL to about 190 mg/mL.

15. The single-use or multi-use vial of claim 14, wherein the formulation has an anti-APRIL antibody concentration of about 20 mg/mL.

16. The single-use or multi-use vial of claim 14, wherein the formulation has an anti-APRIL antibody concentration of about 150 mg/mL.

17. The single-use or multi-use vial of one of claims 14-16, containing a volume of 5 mL of the formulation.

18. A pre-filled syringe, autoinjector, or injector pen comprising the antibody formulation of one of claims 1-12.

19. The pre-filled syringe, autoinjector, or injector pen of claim 18 containing a volume of between about 0.5 mL and about 10 mL of the formulation having an anti-APRIL antibody concentration of between about 20 mg/mL to about 190 mg/mL.

20. The pre-filled syringe, autoinjector, or injector pen of claim 19, wherein the formulation has an anti-APRIL antibody concentration of about 20 mg/mL.

21. The pre-filled syringe, autoinjector, or injector pen of claim 19, wherein the formulation has an anti-APRIL antibody concentration of about 150 mg/mL.

22. The pre-filled syringe, autoinjector, or injector pen of one of claims 19-21, containing a volume of about 2 mL of the formulation.

23. ~~A method of administering an anti-APRIL antibody to an individual in need thereof comprising administering~~Use of the formulation of one of claims 1-12 in the manufacture of a medicament for treating IgA nephropathy, wherein the formulation is to be administered by subcutaneous injection into ~~the~~ an individual in need thereof.

24. ~~A method~~The use according to claim 23, wherein ~~the method comprises repeating~~ the administration is to be repeated on at least an every week (QW) schedule for at least 2 administration cycles.

25. ~~A method~~The use according to claim 23, wherein ~~the method comprises repeating~~ the administration is to be repeated on at least an every two weeks (Q2W) schedule for at least 2 administration cycles.

26. ~~A method~~The use according to claim 23, wherein ~~the method comprises repeating~~ the administration is to be repeated on at least an every 4 weeks (Q4W) or monthly (QMT) schedule for at least 2 administration cycles.

27. ~~A method~~The use according to one of claims 23-26, wherein a total dose of between about 10 mg to about 1350 mg of the anti-APRIL antibody is to be administered per dosing event.

28. ~~A method~~The use according to claim 27, wherein about 2 mL of the formulation at a concentration of about 150 mg/mL of the anti-APRIL antibody is to be delivered per administration, and each dosing event comprises one or more of said administrations.

29. ~~A method~~The use according to claim 27, wherein about 4 mL of the formulation at a concentration of about 150 mg/mL of the anti-APRIL antibody is to be delivered per administration, and each dosing event comprises one or more of said administrations.

30. ~~A method~~The use according to one of claims 23-29, wherein the formulation is to be subcutaneously administered into a site in the individual's thigh, abdomen, or upper arm.

31. ~~A method of administering an anti-APRIL antibody to an individual in need thereof comprising administering~~Use of the formulation of one of claims 1-12 in the manufacture of a medicament for treating IgA nephropathy, wherein the formulation is to be administered by intravenous infusion into ~~the~~ an individual in need thereof.

32. ~~A method~~The use according to claim 31, wherein ~~the method comprises repeating~~ the administration is to be repeated on at least a QW schedule for at least 2 administration cycles.

33. ~~A method~~The use according to claim 31, wherein ~~the method comprises repeating~~ the administration is to be repeated on at least a Q2W schedule for at least 2 administration cycles.

34. ~~A method~~The use according to claim 31, wherein ~~the method comprises repeating~~ the administration is to be repeated on at least a Q4W or monthly schedule for at least 2 administration cycles.

35. ~~A method~~The use according to any one of claims 31-34, wherein the intravenous infusion comprises:

~~diluting~~ the formulation of one of claims 1-12 diluted to a concentration of between about 0.1 mg/mL to about 10 mg/mL in 0.9% saline; and

~~administering~~ a total dose of between about 10 mg to about 1350 mg of the anti-APRIL antibody is to be administered to the individual in a single intravenous dose of the diluted formulation over a period of about 2 hours.

36. ~~A method~~The use according to claim 35, wherein 15 mL of the formulation at a concentration of 20 mg/mL is to be added to 235 mL of 0.9% saline to provide the intraveneous dose at a concentration of 1.2 mg/mL.

37. ~~A method of administering an anti-APRIL antibody to an individual in need thereof comprising administering~~Use of an anti-APRIL antibody in the manufacture of a medicament for treating IgA nephropathy, wherein the anti-APRIL antibody is to be administered by a loading/maintenance administration protocol to an individual in need thereof.

38. ~~A method~~The use according to claim 37, wherein the loading component of the loading/maintenance administration protocol comprises one or more administrations of the anti-APRIL antibody at a higher concentration than the anti-APRIL antibody concentration in the maintenance component of the loading/maintenance administration protocol.

39. ~~A method~~The use according to claim 37, wherein the loading component of the loading/maintenance administration protocol comprises one or more administrations of the anti-APRIL antibody at a higher frequency than the frequency of administration of the anti-APRIL antibody in the maintenance component of the loading/maintenance administration protocol.

40. ~~A method~~The use according to one of claims 37-39, wherein the loading component of the loading/maintenance administration protocol comprises one or more administrations of the anti-APRIL antibody at a different route than the route of administration of the anti-APRIL antibody in the maintenance component of the loading/maintenance administration protocol.

41. ~~A method~~The use according to claim 37, wherein the loading component of the loading/maintenance administration protocol comprises one or more intravenous administrations of the anti-APRIL antibody and the maintenance component of the

loading/maintenance administration protocol comprises one or more subcutaneous administrations of the anti-APRIL antibody.

42. ~~A method~~The use according to one of claims 37-41, wherein the anti-APRIL antibody is an antibody formulation according to one of claims 1-12.

43. ~~A method~~The use according to one of claims 23-41, wherein the individual in need thereof has a serum IgA level greater than 4g/L.

44. ~~A method~~The use according to one of claims 23-41, wherein the individual in need thereof is an IgA nephropathy patient.

45. ~~A method~~The use according to one of claims 23-41, wherein the individual has a hyperimmunoglobulinemia.